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Abstract
There is a growing public concern about the lack of reproducibility of experimental data published 
in peer-reviewed scientific literature. Herein, we review the most recent alerts regarding 
experimental data quality and discuss initiatives taken thus far to address this problem, especially 
in the area of chemical genomics. Going beyond just acknowledging the issue, we propose a 
chemical and biological data curation workflow that relies on existing cheminformatics 
approaches to flag, and, when appropriate, correct possibly erroneous entries in large 
chemogenomics datasets. We posit that the adherence to the best practices for data curation is 
important for both experimental scientists who generate primary data and deposit them in 
chemical genomics databases and computational researchers who rely on these data for model 
development.
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1. Introduction
Massive screening of large chemical libraries against panels of biological targets (e.g., 
kinases, GPCRs, or cytochromes)1 have led to the rapid expansion of publicly available 
chemogenomics repositories such as ChEMBL2, PubChem3, or PDSP4. These depositories 
fuel the initiatives such as the Big Data to Knowledge (BD2K) program at the NIH (https://
datascience.nih.gov/bd2k) and enable the development of computational models of chemical 
bioactivity to guide chemical probe and drug discovery projects.5,6
The excitement concerning the growth and availability of chemogenomics data 
notwithstanding, many serious alerts concerning poor quality and irreproducibility of both 
chemical and biological records have appeared in the literature7,8. For example, Olah et al.9 
showed that on average there were two molecules with erroneous chemical structures per 
each medicinal chemistry publication with an overall error rate of 8% for compounds 
indexed in the WOMBAT database10. Similarly, Young et al.11 found error rates for 
chemical structures in several public and commercial databases ranging from 0.1 to 3.4% 
depending on the nature of the database. Conversely, looking at the biological data accuracy, 
Prinz et al.12 observed that only 20–25% of published assertions concerning purported 
biological functions for novel deorphanized proteins was consistent with the Bayer’s in-
house findings. Begley and Ellis13 discussed a similar analysis performed at Amgen, 
yielding an even lower rate of reproducibility of 11%. Kramer et al.14 analyzed the 
experimental uncertainty of 7,667 independent measurements for 2,540 protein-ligand 
systems extracted from ChEMBL12; they found a mean error of 0.44 pKi units and a 
standard deviation of 0.54 pKi units.
In some cases, subtle experimental details such as differences in biological screening 
technologies were the source of inconsistency. For instance, Ekins et al.15 observed that the 
type of dispensing techniques (tip-based versus acoustic) used in HTS could significantly 
influence the experimental responses measured for the same compounds tested in the same 
assay; they also showed that these variations could dramatically affect both the prediction 
performances and interpretation of computational models built for that dataset. While both 
dispensing techniques are acceptable, this example illustrates the sensitivity of molecular 
modeling results to even subtle experimental variations sometimes well understood only by 
specialists in the respective experimental techniques.
A recent editorial in Nature Chemical Biology16 discussed the urgent need to address the 
problem of data reproducibility. This problem was also given scrupulous attention by the 
NIH leadership in another Nature publication17 co-authored by the NIH Director Francis 
Collins and the Principal Deputy Director Lawrence Tabak. A recent virtual issue of Nature 
summarizing all publications on this subject further highlighted the significance of the 
irreproducibility issue for modern research18. In examining various causes of this problem, 
these papers mainly alluded to the incorrect and inappropriate use of statistics, the clear 
limitations of preclinical models, and the selective data presentation combined with poor-to-
mediocre study design. To start dealing with this issue, Nature recently reinforced the 
acceptance criteria for manuscripts by removing the space restrictions for method sections 
and requesting to have external statisticians to verify the correctness of statistical tests 
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reported in the manuscripts considered for publication. This policy change has caused other 
journals of the Nature family to follow the suit19; and now, the NIH maintains the current list 
of journals and associations or societies publishing preclinical research that endorse NIH-
supported principles and guidelines facilitating the reproduction of published experiments. 
NIH also started a new “rigor and reproducibility” web portal20 in order “to communicate 
NIH endorsed principles and guidelines […] concerning rigor and reproducibility”.
Given that even data published in the highest-ranking peer reviewed journals can suffer from 
poor reliability, it is non-trivial to compile, integrate, and utilize chemogenomics data from 
any source without at least minimum scrutiny. Data curation is especially critical for 
computational modelers because their success depends inherently on the accuracy of the data 
used for model development. Previously, we21 and others11 have demonstrated that the 
prediction performances of QSAR models can be affected by inaccurate and inconsistent 
representations of chemical structures. In the first paper of this series, we have proposed a 
workflow focusing on chemical data curation21. However, biological data quality also has a 
direct influence on model accuracy. Recently, we articulated a need to develop a 
comprehensive chemical-biological data curation workflow that addresses the accuracy of 
both chemical structures and bioactivities in chemical genomics datasets22. Herein, we 
extend our previous work on chemical data curation21 and expand upon general principles 
outlined in the recent brief communication.22 We propose an integrated chemical and 
biological data curation workflow incorporation specific protocols for curating both 
chemical structures and bioactivities in chemical genomics databases that should precede 
any model development. We posit that both experimental and computational researchers 
should consider the proposed workflow as a practical guide to the chemogenomics data 
curation that should be accomplished prior to or in conjunction with the data deposition into 
public repositories and databases. We expect that adherence to these best practices will 
prevent the proliferation of irreproducible data in both publications and online repositories 
and improve the accuracy of data models.
2. An Integrated Workflow for Chemical and Biological Data Curation
Curating both chemical and biological data, i.e., verifying the accuracy, consistency, and 
reproducibility of the reported experimental data is critical for the success of any 
cheminformatics studies, but it is especially true for Quantitative Structure-Activity 
Relationships (QSAR) modeling11,21. Curation of chemical structures is a non-trivial task as 
was shown in our previous publication on this subject21 but curation of biological data is 
even more challenging. Indeed, whereas correct canonical chemical structures based on the 
rules of chemistry do exist for nearly all organic molecules, there are no rules that define 
what the true accurate value of a biological measurement should be. Nevertheless, we posit 
that it is possible to flag (and in some cases even fix) suspicious entries in large 
chemogenomics datasets by applying a series of cheminformatics approaches. To this end, 
we propose an integrated chemical and biological data curation workflow (Figure 1), that 
complements our previous protocol for chemical data curation.21 This workflow includes the 
following key steps:
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(1)
Chemical curation steps include both the identification and correction of structural errors for 
a set of compounds. Depending on the type of analysis and/or modeling study, this curation 
process starts with the removal of incomplete or confusing records, such as inorganics, 
organometallics, counterions, biologics, and mixtures, which most programs for computing 
molecular descriptors are not equipped to handle. Curation elements should also include 
structural cleaning (e.g., detection of valence violations or extreme bond lengths and angles), 
ring aromatization, the normalization of specific chemotypes, and the standardization of 
tautomeric forms. For large arrays of chemicals, most but not all of these tasks are fully 
automated. The treatment of tautomers23 is particularly challenging since the ratio of 
tautomeric forms can be context-dependent. Sitzmann et al.24 established empirical rules to 
consistently treat and represent tautomers to account for the most populated tautomers of a 
given chemical. Numerous software tools are available to help users conduct the 
aforementioned tasks such as Molecular Checker/Standardizer (available in Chemaxon 
JChem25, which is free for academic organizations), RDKit program tools26 (free software) 
or LigPrep (available in the Schrodinger Small Molecule Discovery Suite27 but only for 
subscribers of the Schrodinger license). Importantly, one can integrate all these different 
functions for structural cleaning as a sharable Knime28 workflow to streamline curation 
procedures. For instance, the variation of our original data curation workflow21 was reported 
in a recent publication29.
As bioactive chemicals often incorporate stereocenters, it is highly recommended to verify 
the correctness of stereochemistry: the more asymmetric carbons are present in a molecule, 
the more likely are the errors in their assignment. The comparison of that chemical entry to 
similar compounds in online databases may facilitate the detection of incorrect structures 
and erroneous stereocenters. To this end, PubChem3 recently implemented a structural 
standardization workflow for ensuring that all chemicals stored in the database are 
processed, represented, and standardized the same way using a structured and consistent 
protocol. Furthermore, Chemspider30 represents a great example of a crowd-curated 
database illustrating the power of community engagement and expertise for chemical 
structure verification. For any chemical, Chemspider indicates how many stereocenters are 
properly defined and confirmed. Despite these automatic curation tools, manual curation is 
still critical because some errors obvious for chemists are not obvious for computers.
Even in the case of large datasets in excess of thousands of compounds, we strongly 
recommend to check manually at least a fraction of the dataset. For instance, to reduce the 
amount of effort one could check only compounds with complex structures or having a large 
number of atoms. The most obvious advice is to generate a representative sample of the 
dataset and check it for the presence of potential erroneous structures.21 In addition, 
identification of the subset of “suspicious” compounds with high probability of error for 
additional checking is described in the step 7 of the proposed workflow. However, inspection 
or even rejection of the entire data set, however long it may take, may become unavoidable if 
significant amount of errors is found.
Another solution for processing large data sets, where manual checking of structures and 
data is almost impossible, is an engagement of scientific community in crowd-sourced 
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curation efforts. This approach seems to be very promising, especially given the success of 
similar initiatives in Chemspider or Wikipedia, where the quality of crowd-curated chemical 
data is comparable or higher than the quality of expert-curated data in databases such as 
ChemIDPlus, DrugBank, etc.
(2)
Processing of bioactivities for chemical duplicates. Often, the same compound is recorded 
multiple times in chemogenomics depositories31. For instance, identical chemicals ordered 
from different suppliers can be tested in the same assay, sometimes in different laboratories, 
resulting in different internal substance IDs, different experimental responses, and in fine 
multiple records32. QSAR models built with datasets containing many structural duplicates 
will have artificially skewed predictivity (over-optimistic if activities are similar, or of low 
accuracy if activities are dissimilar) due to the likely presence of the same compounds in 
both training and test sets21. Dealing with this issue requires the detection of structurally 
identical compounds in a dataset followed by the comparison of bioactivities reported for the 
retrieved duplicates. The definition of “identical” compounds depends on how the chemical 
similarity is computed and the type of chemical descriptors used (e.g., 1D or 2D descriptors 
cannot differentiate between stereoisomers). Processing of structural duplicates solely based 
on chemical names, SMILES, and/or CAS numbers is inefficient compared to using InChI 
and/or 2D structures (see an example in Figure 2). We use standard molecular indices 
(available in both RDKit and CDK toolkits) and fragment descriptors to compute the 
similarity between any two compounds; if the similarity is equal to 1, then the two 
compounds are recognized as duplicates. Freely-accessible tools such as ISIDA-Duplicates33 
or HiT QSAR34 can identify pairs of duplicates based on molecular descriptors or canonical 
numeration of chemical graphs computed for each molecule. For instance, we have 
identified more than 1,200 pairs of structural duplicates (with different substance IDs from 
different chemical vendors) in the NCGC Cytochrome P450 screening collection32 in which 
over 17,000 compounds were tested against five major P450 isozymes. Importantly, as many 
as 874 out of 1,200 pairs had different reported CYP bioprofiles (see Supplementary Table 
1) requiring further examination and curation prior to QSAR modeling.
Finding duplicates in a set of chemicals is relatively trivial with the aforementioned 
similarity-based programs but the automatic comparison of the bioprofiles for duplicates is 
not. If the two bioprofiles are identical, one structure can simply be deleted. The task 
becomes more difficult and time-consuming when these experimental bioprofiles are not 
identical. In such cases, there are several scenarios to consider:
a. The property value for one compound is clearly wrong (e.g., mis-annotation in 
the database, labelling error, wrong unit) in which case a neighborhood analysis 
can help identifying which value is most likely to be correct (see an example in 
Figure 3);
b. The curation workflow (e.g., the removal of salts and counterions, the 
standardization of chemical groups) has changed the representation of one 
substance (or both) and created duplicates. In this case, one should check the 
original record and verify whether the difference in activity can be explained by 
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the fact that in one case the compound has been tested in its neutral form and in 
the other case, the compound was tested as a salt. As these instances are common 
with salts, we recommend determining early on how many chemical salts are 
present in the dataset and deciding whether only neutral compounds must be 
considered. In the situation when only a few salts have dramatically different 
properties than those compounds in their neutral forms, we recommend 
removing them from the dataset. Otherwise, they will become prediction outliers 
if compounds in neutral form are used for QSAR modeling.
c. Experimental variability may be at the origin of the discordance for the 
duplicates’ bioprofiles. A specific set of actions is required for the analysis of 
experimental variability (see next section).
In our practice, activity values expressed in different units are among the most common 
sources of discordance for duplicates bioprofiles (e.g., a compound recorded as a millimolar 
inhibitor in database A and as a micromolar inhibitor in database B). The automatic 
treatment of duplicates is obviously facilitated when all bioactivities are expressed in the 
same units35. As the last resort, suspicious pairs of duplicates with different bioactivities can 
be discarded altogether; however, the prediction of such compound bioactivity with a QSAR 
model built with the remaining compounds could help establishing which of the conflicting 
values is likely to be correct (see also step 7 for more details).
(3)
Analysis of inter- and/or intra-lab experimental variability. The analysis of bioactivities for 
duplicate compounds also enables the evaluation of both inter- and intra-lab experimental 
variability. It is a common laboratory practice to measure the bioactivity of a compound in 
multiple replicates in the same assay. For a given ADMET endpoint (e.g., metabolic 
stability) with tens of thousands of measured data points available in-house, Big Pharma 
companies often test hundreds of chemicals in duplicates or triplicates. Datasets containing 
such information are particularly helpful to study the global experimental variability of an 
assay (Figure 4) across multiple series of compounds (e.g., experimental variability for most 
active compounds versus most inactive ones) as well as to analyze the local variability 
within a given range of bioactivity or within a chemical series. Moreover, the bioactivity of 
reference compounds can even be measured hundreds of times over many months and even 
years, offering the ultimate assessment of the experimental variability using appropriate 
metrics35. As such type of data is typically not accessible to academic researchers, 
alternative approaches could be used to assess the experimental variability and its influence 
on models’ prediction performances.
Modelers could rely on data precision as reported in a publication (e.g., “± 0.2 log units”), 
which is often associated with one (or a few) data point(s) 35. In practice, it means that the 
experimental variability should be assessed as constant (Figure 4A). As a result, the highest 
expected accuracy a QSAR model may not be higher than the experimental variability. For 
instance, if the mean absolute error for a model is reported to be 0.1 log unit despite an 
experimental variability close to 0.3 log units, it may be indicative of overfitting.
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However, the experimental variability is not necessarily the same for all compounds in a 
dataset. As illustrated in Figure 4, the assay’s variability can be considerably lower for 
compounds with extreme activities (Figure 4B), or for the more active compounds (Figure 
4C), or the less active compounds (Figure 4D). Obviously, the variability can also be random 
(Figure 4E). We highlight these different profiles of experimental variability as they may 
have different effect on the prediction performances of QSAR models. For instance, the 
higher experimental variability for less active compounds may have negligent effect on the 
model accuracy if such compounds are chemically distinct from more active and more 
chemically similar molecules.
For modelers who may have access to large screening data collections, we recommend 
analyzing the baseline history of the target/endpoint of interest as well as all measurements 
obtained for the reference controls. The baseline history (e.g., per plate, per batch, per week, 
per month, etc.) facilitates the identification of false-positives and false-negatives in HTS 
screening (cf. software tools such as HTS Navigator36).
It is extremely difficult to assess the inter-laboratory variability since it involves the 
identification of duplicate compounds having two (or more) different bioactivity values 
measured in two (or more) independent laboratories. Such replicate measurements are rarely 
done and/or rarely published, except for some very well-known active (and/or toxic) 
molecules and reference controls. Drawing any conclusions requires the analysis of many 
duplicates in addition to globally-accepted estimation of experimental reproducibility 
associated with a particular assay (e.g., the overall reproducibility is ~85% for the Ames 
mutagenicity test37).
To summarize this step, we shall emphasize that although the duplicated records should be 
excluded prior to modeling, the analysis of duplicates present in the original dataset is 
extremely useful to estimate the experimental uncertainty of the data. Grouping of duplicates 
by data source allows to estimate the inter- and intra-lab variability. In case of high (>30%) 
discordance between duplicates no reliable models could be obtained. Thus, based on such 
estimates we could decide (i) whether the development of reliable models is possible for a 
dataset compiled from the different sources; (ii) whether we should use the data generated in 
different labs separately; or (iii) whether no model development is possible at all.
(4)
Exclusion of unreliable data sources: The identification and exclusion of data sources with 
inconsistencies, biases, systematic errors, and/or outdated records is not trivial. One can 
consider any data source unreliable if there are statistically significant differences in 
measured bioactivities for a consistent fraction of chemicals. An example could be given by 
a paper or a series of papers published by the same lab that is not conducting the assay of 
interest the same way as the majority of research groups do. In such case, the associated data 
points should probably not be part of the integrated modeling set for developing predictive 
QSAR models. Other examples of experimental discrepancies relate to chemogenomics 
measurements published prior to a radical change in the protocol for a given assay, or 
experimental data from a company site different from the other sites of the same company 
(e.g., one site is running an assay at pH=7.0 whereas the other site is running the same assay 
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at pH=8.0). These data points are not incorrect per se but they will likely be problematic and 
even incompatible if they are integrated in the same dataset.
It is critical to establish “golden lists” of carefully curated chemical databases. Our recent 
experience in developing “The Children’s Pharmacy Collaborative™” database38 shows that 
establishing such “golden list” of sources is rather tedious due to the missing and unclear 
information requiring expert analysis. For instance, marimastat is a drug approved for the 
treatment of various cancers according to DrugBank but this compound was annotated 
elsewhere39 as performing poorly in clinical trials for the same indication so its development 
was terminated. Besides the elimination of unreliable sources as a whole, the use of strict 
filters35 to identify unwanted data points is an important approach to better ensure the 
consistency and validity of a set of compounds prior to model development. For instance, 
Kalliokoski et al.35 tested a series of filters for automatic preprocessing of IC50 values 
extracted from ChEMBL14, e.g., automatic deletion of data points taken from reviews or 
articles with undefined authors, deletion of records with unclear units, or records with 
extreme values.
(5)
Detection and verification of activity cliffs: It is important to identify pairs of molecules 
sharing very high structural similarity but having drastically different bioactivities. Such 
“activity cliffs”40 have been viewed as one of the major challenges for accurate bioactivity 
prediction using cheminformatics approaches, especially QSAR models (e.g., by affecting 
dataset “modelability”41) or any other approach based on chemical similarity. There are 
different categories of activity cliffs40 depending on how the similarity of compounds is 
measured (e.g., 2D, 3D, matching molecular pairs). Prior to initiating the computational 
study of a dataset, all activity cliffs must be detected, verified, and treated. For each pair of 
compounds forming an activity cliff, there are two main questions to address: Is it a true 
cliff? If yes, (how) should these compounds be incorporated in the modeling dataset? The 
aforementioned software for duplicate searches is useful for retrieving activity cliffs. 
However, once identified, the activity cliff-forming pair of compounds needs to be analyzed 
according to the following principles (Figure 5):
a. Bioactivities associated with each compound must be carefully checked against 
the original data source for accuracy. Mislabeling is one of the main sources of 
false activity cliffs: for instance, compound A is a 10 nM inhibitor (very active) 
and its most similar molecule in the dataset is compound B annotated as 12 mM 
inhibitor (inactive). An example is given by the case discussed in Figure 3 where 
using a high activity value for (deemed inaccurate by the chemical similarity 
clustering as discussed above) Tocris-0740 would make it appear as an activity 
cliff as compared to any chemically similar molecule in the same table. It is also 
possible that merely the wrong unit (mM instead of nM) may have been reported 
and inserted in the database;
b. 2D structural differences between the two compounds must be analyzed and 
interpreted in the context of the underlying assay or target. To do so, we 
recommend analyzing chemical features differing between the two compounds: 
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what is this chemical feature (e.g., a carboxylic moiety, a slightly longer carbon 
chain, an additional hydroxyl group, a different substituent attached to an 
aromatic ring)? Is it likely to be responsible for that dramatic change in activity? 
If no, there is likely something wrong with the record. If yes, what descriptors 
can reflect such an extreme structure-activity relationship?
c. 3D structural differences should also be considered. For such activity cliffs, very 
significant differences in experimental bioactivities can be due to minor changes 
in the receptor-ligand interactions. Thus, it makes sense to study 2D activity 
cliffs identified in a dataset by analyzing them in 3D, preferably in the context of 
receptor-ligand interactions. If the 3D structure of the target is known as well as 
the binding mode of at least one compound from the pair under consideration, it 
is feasible to compare the difference in receptor-ligand interactions. Tools like 
the structure builder in Schrodinger’s Maestro are very useful in that regard. 
These differences in receptor-ligand interactions (e.g., steric constrains, H-bond 
or π-π stacking disruption) might be at the origin of the cliff formation. If no 3D 
structure is available for the receptor, one can still superimpose the two 
compounds in 3D and study how these two conformations differ from each other. 
We should still underline that determining the 3D conformation of a flexible 
chemical is very much context-dependent and even the “active conformation” of 
a molecule in the binding pocket of an enzyme corresponds to an ensemble of 
local metastable conformations. Therefore, the calculation of 3D descriptors for 
chemicals requires detailed justification of the choice of molecular 
conformations.
d. Finally, the modeler should decide whether to keep or discard any activity cliff-
forming compounds in the modeling set.
Interestingly, one can enrich the set of chemical descriptors used for QSAR modeling for 
better discriminating activity cliffs: for example, 2D descriptors cannot differentiate 3D 
activity cliffs; therefore, adding chirality-encoding descriptors may help converting a 2D 
activity cliff into structurally more different compounds. Moreover, the researcher can 
choose a different modeling technique (e.g., docking) to better model the cliffs. In a recent 
study, Hu and Bajorath42 have compared 2D versus 3D activity cliffs identified for different 
targets such as β-secretase1 and factor Xa. They found that more than 60% of 2D activity 
cliffs could be distinguished at the 3D level. At the same time, these authors noticed that 
some 3D activity cliffs with no notable differences regarding their receptor-ligand 
interaction could easily be distinguished at the 2D level. Thus, 2D and 3D similarity 
assessment should complement each other.43
(6)
Calculation and tuning of the dataset modelability index (MODI): Recently, we introduced 
the concept of “dataset modelability”41, i.e., an a priori estimate of the feasibility to obtain 
predictive QSAR models for a given set of chemicals. This concept has emerged from 
analyzing the impact of activity and similarity cliffs on the overall performance of QSAR 
models40. The calculation of MODI helps modelers to (i) quickly evaluate the feasibility of 
obtaining QSAR models with significant predictive power; (ii) identify a subset of 
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compounds with higher modelability (especially when the activity distribution is biased 
towards one activity class or an activity range); and (iii) choose which set of chemical 
descriptors will likely produce QSAR models of the higher prediction power. If the MODI 
index is low, then the development of QSAR model for the respective dataset is not 
recommended. One should note that different sets of 2D chemical descriptors will return 
different but similar MODI values for a given dataset. Switching from 2D to 3D 
descriptors44 or from chemical to biological descriptors45 can help to increase the 
modelability of a given dataset. This work was recently extended by Marcou et al.46
(7)
Consensus QSAR prediction to curate mislabeled compounds. The underlying idea of 
consensus predictions is that an implicit SAR for a given dataset can be formally manifested 
by a variety of QSAR models built with different types of molecular descriptors and diverse 
machine learning approaches. Rigorously built individual models form an ensemble that 
allows for consensus bioactivity prediction using all models at once. The development of 
consensus models is generally recommended as they reach higher prediction performances 
as well as better dataset coverage due to their larger applicability domains47. As a result, 
consensus models can be used to flag and sometimes correct the experimental measurements 
of mislabeled compounds in a dataset. Consensus models can also be utilized to forecast the 
properties of pairs of stereoisomers and potentially identify the mis-annotated ones. Briefly, 
a compound can be considered “suspicious” and selected for deeper examination if: (i) all 
models involved in the consensus ensemble failed to predict its activity accurately; and (ii) it 
belongs to a tight cluster of two or more structurally similar compounds where all the other 
compounds have different (but mutually similar) bioactivities. We have demonstrated the 
success of this approach using Ames mutagenicity21 data. Employing both manual and 
automatic literature mining tools, our analysis revealed that 31 out of 140 “suspicious” 
compounds (~22.1%) were annotated erroneously in the original dataset. Recently, the same 
approach was used for the identification of mislabeled compounds in the largest set of 
chemical-induced skin sensitization records48 available in the public domain. Thus, 
predictive QSAR models obtained for carefully curated datasets can be successfully 
employed as a key component in biological data curation workflows.
Concluding this section, we shall note that although each step of the developed workflow 
can be done using existing cheminformatics techniques and software tools, project-specific 
decision-making is an inherent part of almost every part of the process. In addition to the 
detection and elimination of erroneous, non-standardized, and duplicated chemical structures 
(steps 1 and 2); records associated with unreliable data sources or high experimental 
variability (steps 3 and 4); structural outliers and unverified activity cliffs (steps 5 and 6), 
some mislabeled compounds can also be identified and corrected (step 7). Moreover, global 
decision regarding the very feasibility of model development could become a necessity when 
analyzing the outcome of the steps 2, 3, and 6. For instance, if duplicate analysis (step 2) 
will show high (>30%) discordance of associated activity values that could not be explained 
by inter-lab variability (step 3) or MODI value (step 6) of the resulting dataset would be 
lower than cut-off value of 0.65, we would not recommend the development of QSAR 
models.
Fourches et al. Page 10
J Chem Inf Model. Author manuscript; available in PMC 2017 October 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sometimes, the dataset curated using the proposed workflow could become too small or 
unbalanced with one activity class underrepresented to ensure the development of reliable 
models. Thus, if after curation the dataset includes less than 40 compounds;47 activity range 
is less than 3 logarithmic units or contains large gaps that exceed 10%–15% of the entire 
range (for continuous datasets);47 one activity class contain less than 20 compounds (for 
binary models),47 we recommend the use of similarity searching or docking (if possible) 
instead of QSAR modeling. At the same time, the curated dataset could be stored and later 
enriched with new experimental data that would make it suitable for modeling.
3. Perspectives
The data-processing steps summarized in the previous section incorporate the key 
procedures our research groups at NCSU and UNC currently employ to prepare, curate, and 
standardize any chemogenomics dataset prior to its modeling. It is important to note that the 
order of execution of these procedures can be modified according to the size and exact 
nature of the underlying dataset. In the absence of such well-defined curation workflow, 
researchers that in any way rely on historical data for planning their future experiments are 
running the risk of conducting their analysis and modeling with incomplete, incorrect, 
inaccurate, inconsistent, or irreproducible data points (the “five i’s” danger)22. In our 
previous study21, we showed that chemical curation was critical to maximize the prediction 
abilities of QSAR models. We cannot stress enough how important data curation is to 
achieve reliable and useful QSAR models.
With the rapid accumulation of experimental data in publicly-available repositories, the 
problem of knowledge extraction from data, i.e., data science, becomes increasingly critical 
to enable further progress of research. The knowledge is summarized in the form of models 
that enable rational, data driven decision support. In a recent famous statement, the President 
of the Royal Society of Chemistry Professor Dominic Tildesley predicted that “the advances 
in modeling and informatics are so dramatic that in 15 years’ time, no chemist will be doing 
any experiments at the bench without trying to model them first”.49 This expectation can be 
extended towards many biological and biomedical disciplines implying that experimental 
scientists will increasingly rely on the power of computational models to rationally direct 
their studies. The aforementioned ability of models to provide as accurate estimates of the 
experimental data as the experiment itself does not appear to be restricted to chemical 
biology. For instance, pharmacokinetic models often yield time-dependent drug 
concentration curves that are more accurate than the experimental ones.50 Specifically, it has 
been acknowledged that individual time-point measurements could be off significantly 
whereas predicted values give accurate results that can be confirmed when the experiment is 
reproduced. However, computational model accuracy depends directly on the accuracy of 
the data used to build a model. This consideration places the issue of data irreproducibility 
and accuracy at the forefront of computational modeling research, emphasizing the need for 
data curation as the first critical step of model development.
The vast majority of synthesized compounds is reported in the literature only once.14 
Moreover, it is uncommon to find their biological assay measurements reported in replicates 
by multiple groups. Therefore, a full analysis of the reliability of all chemical and biological 
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records in a dataset is extremely difficult to accomplish14,35; thus, the most logical way to 
ensure the accuracy of the reported data is to place this responsibility for ensuring data 
accuracy on the experimental researchers who generate data at first. Clearly, experimental 
scientists should know and understand their data the best. Therefore, ideally, the best 
approach to minimizing the risk of errors is to have experimental scientists upload their data 
electronically to the respective databases simultaneously with the manuscript submission. 
This is the standard practice in macromolecular crystallography where coordinates of protein 
or nucleic acid structures must be uploaded to the Protein Data Bank (PDB) prior to the 
manuscript submission. This should also become mandatory for newly synthesized 
compounds tested in bioassays prior to their publication in medicinal chemistry and 
chemical biology journals.
Journal editors should also consider supporting and encouraging the implementation of 
electronic protocols and associated file formats for chemical data storing and sharing. 
Indeed, the pdf format used to store and distribute journal papers is inefficient for extracting 
chemical data, re-plotting the graphs, or mining molecular structures, i.e., the pdf format is 
far from being cheminformatics-ready. Fortunately, new file formats are slowly emerging to 
enable the aforementioned tasks: for instance, MIABE51 and BAO52 were specifically 
designed to ensure a consistent storage, ontology and information architecture to 
characterize bioassays and their results. Extending the use of these formats is the only 
rational way to enable machine-readable descriptions of bioassays, molecular structures, 
experimental protocols, and NMR spectra reported in scientific publications. These formats 
will also facilitate the integration and comparison of experimental data from different 
research groups. Another plausible approach to increase data completeness and accuracy is 
to employ crowd-solving and crowd-checking approaches that will help in discovering and 
correcting erroneous entries in publicly available databases (e.g., Chemspider or Wikipedia). 
For instance, our group had a very encouraging experience with ChEMBL, when a reported 
inaccuracy in β2-adrenergic agonists binding affinity was fixed in less than 24 hours by the 
ChEMBL team at EBI. However, one should note that the traceability of these corrections is 
almost nonexistent, i.e., correcting a pKi value in an online database such as ChEMBL will 
not autocorrect all the instances of that particular record in other online databases, e.g., 
PubChem that includes data from ChEMBL, nor will it correct the same instance in a 
locally-stored SD file. In the absence of such connectivity between databases containing 
similar data, data curation workflows described in this paper should be applied to every 
database and dataset independently.
4. Conclusions
The exploitation of today’s online repositories containing large sets of heterogeneous 
chemogenomics data requires the use of powerful, transparent, and robust data curation 
workflows. Although such procedures are required and implemented for submitting novel 
protein crystal structures to the PDB (e.g., AutoDep Input Tool), curation is still far from 
being condicio sine qua non in chemical and biological data analysis leading to reporting 
erroneous or irreproducible data in published manuscripts. Since the presence of erroneous 
data points is known to cause computational models to fail or have low predictive power, 
chemical biological curation workflows can be utilized to flag (and where possible fix) those 
Fourches et al. Page 12
J Chem Inf Model. Author manuscript; available in PMC 2017 October 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
records and ultimately improve the quality of data analysis and prediction performances of 
modeling techniques (e.g., pharmacophore, QSAR, and docking). Although this Perspective 
focuses predominantly on chemical biology, similar problems are common for the entire 
biomedical research53 and they plague other fields as well, e.g., nanotechnology54.
Reducing the amount of erroneous or irreproducible results requires coordinated efforts 
between research community, funding agencies, and journal publishers. As funding agencies 
such as NIH or NSF are starting to establish data sharing policies, we believe the chemical 
biology community (and for that matter, research community of any data-rich discipline) 
should adopt the culture and mechanisms for data sharing established within the structural 
biology community. To do so, experimental researchers should be provided with 
computational tools to curate, organize, and submit their data to specialized repositories or 
databases. Importantly, these databases should be certified by the respective funding 
agencies and supported by peer-reviewed, competitive grants, which is how Protein 
Databank has been supported for many years. An agreement should be reached between 
funding agencies and scientific journals that no paper reporting new data could be accepted 
without providing a statement from the respective database or repository that they have 
received that data. This would be similar to rules established in structural biology where 
most journals will not even consider a manuscript describing a new X-ray or NMR-
characterized protein structure without a confirmation from the Protein Databank that 
coordinates have been deposited. Such agreements are possible and can be illustrated by the 
practice established by the NIH several years ago that all published papers should be 
uploaded to PubMed Central within a year following the original publication.
The basic gold standard for reporting scientific results and ensuring their correctness will 
always rely on whether or not the experiments described in a study can be reproduced using 
the information provided by the authors. Nevertheless, curation workflows for chemical 
genomics data may contribute to establishing the best practices and culture of data curation 
as an essential component of further progress in our discipline.
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Figure 1. 
General workflow for comprehensive curation of chemogenomics datasets.
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Figure 2. 
Example of duplicate retrieval using PubChem ID, smiles, chemical names, InChI, and 2D 
similarity. Note the 2D similarity was computed as Tanimoto coefficient using CDK 
descriptors and had Tc = 1 (implicating structural duplicates) for the two curated compounds 
(no salts, standardized functional groups and aromatization).
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Figure 3. 
Chemical similarity analysis for a pair of substances with duplicate structures found in the 
NCGC Cytochrome P450 screen32 in which 17,000 compounds were tested against five 
major isozymes. LogAC50 = -8 for CID_6603937 at CYP 3A4 (highlighted by the red circle) 
is automatically flagged as incorrect because highly similar molecules in the same dataset 
have CYP 3A4 activities consistent with an alternative measurement for the same 
compound.
Fourches et al. Page 19
J Chem Inf Model. Author manuscript; available in PMC 2017 October 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Illustration of different types of experimental variability (see text for details).
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Figure 5. 
Initial workflow to analyze activity cliffs.
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